IDO/Tubulin-IN-2 (HT2) is a potent inhibitor of TDO and tubulin, showing significant efficacy against cancer cell lines U87, HepG2, A549, HCT-116, and LO2, with respective IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM. Additionally, IDO/Tubulin-IN-2 markedly enhances antitumor activity [1].

IDO/Tubulin-IN-2 (HT2) (0-50 μM, 4 h) exhibits potent cytotoxicity with IC50 values from 0.036 to 0.43 μM against various cancer cell lines [1]. At 0.1 μM over 24 h, it arrests HepG2 cells in G2 phase, induces apoptosis, promotes PARP proteolytic cleavage, and up-regulates caspase-3 expression [1]. At 0.05 μM, it reduces TDO mRNA expression in a time-dependent manner over 24, 48, and 72 h [1]. After 2 days, it enhances T-cell activation and proliferation, boosting the immune response [1].

IDO/Tubulin-IN-2 (HT2), administered intravenously at a dosage of 30 mg/kg daily for 21 days, considerably suppresses tumor proliferation [1]. Additionally, when given for 29 days using the same dosage and route, it effectively enhances antitumor immunity, thereby augmenting the therapeutic effectiveness against tumors [1].